Gilead Broadens Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing Agreement

Gilead Sciences Signs Royalty-Free Licensing Agreements to Support Potential Future Access to Investigational Obeldesivir for Ebola Prevention

Gilead Sciences, has announced royalty-free voluntary licensing agreements with three generic pharmaceutical manufacturers to support potential future access to its investigational antiviral candidate obeldesivir for post-exposure prophylaxis (PEP) against Ebola Bundibugyo virus disease (BVD). The agreements are intended to strengthen manufacturing preparedness, facilitate technology transfer, and support supply planning while clinical research continues to evaluate the candidate’s potential role in preventing disease following exposure to the virus.

The licensing arrangements cover 127 countries, primarily low- and lower-middle-income nations. Their geographic scope is consistent with Gilead’s existing voluntary licensing agreements for remdesivir for COVID-19 and includes all African countries that have reported cases during the current Ebola BVD outbreak.

Through these agreements, Gilead aims to establish the groundwork for a potential manufacturing and supply network that could help make obeldesivir available in affected regions if clinical studies demonstrate benefit and the necessary regulatory authorizations are obtained. The arrangements are designed to support preparedness before a potential future need for widespread access arises, rather than indicating that obeldesivir has already been approved or is currently available as a preventive treatment for Ebola BVD.

The agreements come as the company continues to participate in broader efforts to address the current outbreak through clinical research, collaboration with public health organizations, and donations of antiviral medicines for investigational use.

Licensing Agreements Support Potential Access Across 127 Countries

The three generic manufacturers entering into voluntary licensing agreements with Gilead are Dr. Reddy’s Laboratories, Eva Pharma, and Ferozsons Laboratories.

Under the agreements, these companies will be authorized to manufacture and supply obeldesivir within the licensed territories, provided that clinical data support its use and the relevant regulatory authorizations are secured.

The arrangements are royalty-free, meaning the generic manufacturers will not be required to pay royalties to Gilead under the licensing agreements. The goal is to establish the manufacturing capabilities and operational arrangements that may be needed to support future access, particularly in countries where Ebola outbreaks can place significant pressure on healthcare systems and public health infrastructure.

Technology transfer discussions between Gilead and the manufacturers are already underway. The company is also discussing potential agreements with additional manufacturers, which could further strengthen manufacturing preparedness and supply capacity if obeldesivir demonstrates clinical benefit.

Establishing manufacturing readiness during clinical development may help reduce delays if the candidate eventually receives regulatory approval for the intended use. It also provides an opportunity for generic manufacturers to prepare production processes and supply arrangements in advance, rather than beginning these activities only after a public health emergency creates urgent demand.

The 127-country scope is particularly significant because it includes countries across regions where access to innovative medicines may be constrained by economic, manufacturing, and distribution challenges. By working with established generic pharmaceutical manufacturers, Gilead intends to support a potential supply framework that could reach populations in countries with limited resources.

However, the company emphasized that obeldesivir remains investigational. Although the antiviral has demonstrated preclinical activity against multiple filoviruses, it has not been approved for post-exposure prophylaxis of filovirus disease in any country.

Phase 3 EBO-PEP Trial Evaluates Obeldesivir for Ebola Prevention

The licensing agreements are being established while the ongoing Ebola Post-Exposure Prophylaxis (EBO-PEP) field trial evaluates obeldesivir in individuals at high risk of developing Ebola Bundibugyo virus disease.

EBO-PEP is a Phase 3 randomized, placebo-controlled clinical trial coordinated by ALIMA and its partners. The study is designed to investigate whether obeldesivir can help prevent Ebola BVD in people who have been exposed to the virus or are otherwise considered at high risk of infection.

Post-exposure prophylaxis refers to the administration of a preventive intervention after a person has potentially been exposed to an infectious disease. In the context of Ebola, this approach is particularly important because close contacts of confirmed cases may face an increased risk of infection and require rapid medical assessment and monitoring.

The EBO-PEP study is intended to generate clinical evidence regarding the safety and potential effectiveness of obeldesivir when used in this setting. Its randomized, placebo-controlled design will allow researchers to compare outcomes between participants receiving the investigational antiviral and those receiving placebo.

The results will be important in determining whether obeldesivir could become a potential preventive option for individuals at high risk of Ebola BVD following exposure.

The trial is part of a broader scientific effort to identify effective interventions against Bundibugyo virus disease, an Ebola virus disease caused by Bundibugyo virus. Different Ebola virus species can cause outbreaks with substantial public health consequences, and treatment or prevention options may vary depending on the virus involved.

For Gilead, the EBO-PEP trial represents an important component of its strategy to evaluate antiviral medicines against emerging infectious diseases while preparing for potential future access requirements.

Gilead Highlights the Importance of Early Outbreak Preparedness

Jaime McCoy, Vice President of Gilead Patient Solutions at Gilead Sciences, said that responding to emerging infectious diseases requires scientific innovation as well as early planning and collaboration to ensure that effective medicines can reach affected populations as quickly as possible.

McCoy emphasized that the agreements reflect Gilead’s commitment to preparing for potential future access while clinical research is still underway.

The company aims to establish manufacturing and supply arrangements in advance so that it may be better positioned to respond if investigational medicines demonstrate benefit and receive regulatory approval.

This approach recognizes that the availability of a promising antiviral candidate alone may not be sufficient during an infectious disease outbreak. Manufacturing capacity, technology transfer, regulatory readiness, procurement planning, and distribution networks can all influence how quickly a medicine reaches patients.

By engaging generic manufacturers during the clinical development process, Gilead intends to address some of these practical considerations before a potential approval decision.

The company is also working with public health organizations, governments, and global health partners as part of its broader outbreak preparedness strategy. These collaborations are intended to support coordinated responses to emerging infectious disease threats and improve the ability of healthcare systems to access potential treatment and prevention options.

Remdesivir Licensing Agreements Expanded to Include Filovirus Disease

In addition to the new obeldesivir licensing arrangements, Gilead is updating its existing voluntary licensing agreements for remdesivir to include filovirus disease.

The expansion is intended to support potential future access to remdesivir for the treatment of Ebola BVD, subject to evidence from the ongoing World Health Organization (WHO)-sponsored PARTNERS trial and any applicable regulatory approvals.

The PARTNERS trial is part of international research efforts to identify effective treatments for Bundibugyo virus disease. The study is intended to generate evidence that can help inform decisions about potential therapeutic approaches for patients affected by the disease.

If the trial supports the use of remdesivir as a treatment and the required regulatory approvals are obtained, the expanded licensing arrangements could provide a framework for generic manufacturers to supply the medicine in the licensed territories.

The inclusion of filovirus disease in the remdesivir agreements reflects Gilead’s efforts to use its existing licensing infrastructure to support potential access to antiviral treatments beyond their original approved indications.

The company has previously established voluntary licensing arrangements for remdesivir in connection with COVID-19. Extending the scope of these agreements to include filovirus disease may help build on existing manufacturing and supply relationships while supporting preparedness for future Ebola-related medical needs.

As with obeldesivir, any potential use of remdesivir for Ebola BVD remains dependent on clinical evidence and applicable regulatory decisions. The licensing arrangements themselves do not represent regulatory approval or confirmation of clinical effectiveness for this indication.

More Than 2,000 Vials of Remdesivir Donated to Kenya

As part of its response to the current Ebola BVD outbreak, Gilead recently donated more than 2,000 vials of remdesivir to Kenya.

The donation is intended to support investigational use of the antiviral as a potential treatment and post-exposure prophylaxis option for people with confirmed Ebola BVD or individuals who have experienced close-contact exposure.

The donation reflects the company’s efforts to support public health responses while clinical research into potential treatment and prevention strategies continues.

Gilead has also provided compassionate-use donations of remdesivir to the Democratic Republic of the Congo (DRC), Uganda, and Kenya. Across these countries, the donations have totaled more than 38,000 vials.

Compassionate use can provide access to investigational medicines for patients in certain circumstances when approved treatment options may be limited or unavailable. Such access is generally subject to applicable regulatory requirements and medical oversight.

The donations are part of Gilead’s broader response to the outbreak and demonstrate its involvement in efforts to support healthcare providers and public health partners dealing with Ebola BVD.

The company is combining these activities with its longer-term approach to outbreak preparedness, which includes clinical studies, manufacturing planning, technology transfer, and collaboration with governments and global health organizations.

Obeldesivir’s Potential Role in Filovirus Disease

Obeldesivir is an investigational antiviral candidate being evaluated for its potential to prevent Ebola BVD following exposure. Gilead has reported that the compound has demonstrated preclinical activity against multiple filoviruses.

Filoviruses are a group of viruses that includes the viruses responsible for Ebola virus disease. These infections can cause severe illness and may lead to outbreaks requiring rapid public health intervention, specialized medical care, and coordinated responses across affected communities.

Developing antiviral medicines for filovirus infections presents significant scientific and operational challenges. Clinical research is needed to establish whether a candidate is safe and effective in the intended population, while manufacturing and distribution capabilities must be prepared to support access if the medicine is eventually authorized.

Obeldesivir’s evaluation in the EBO-PEP trial is focused specifically on its potential use as post-exposure prophylaxis for individuals at high risk of developing Ebola BVD.

The candidate’s preclinical activity across multiple filoviruses provides a scientific basis for continued investigation, but preclinical findings do not establish clinical effectiveness in humans. Results from the ongoing clinical trial will be essential to determine whether the medicine offers a meaningful preventive benefit.

The royalty-free agreements with Dr. Reddy’s Laboratories, Eva Pharma, and Ferozsons Laboratories are intended to ensure that manufacturing and supply preparations can progress alongside this research.

Integrated Strategy Combines Research, Manufacturing and Global Collaboration

Gilead’s latest licensing announcement forms part of a broader strategy to strengthen preparedness for emerging infectious disease outbreaks.

The company’s approach includes several interconnected activities: evaluating investigational antivirals through clinical research, establishing manufacturing readiness, transferring technology to qualified generic manufacturers, planning potential supply arrangements, and collaborating with public health agencies and governments.

These efforts are intended to address the challenges that can arise when an outbreak requires rapid access to medical countermeasures.

The new obeldesivir agreements establish a potential pathway for generic manufacturing across 127 primarily low- and lower-middle-income countries. The inclusion of countries affected by the current Ebola BVD outbreak is intended to ensure that regions with reported cases are covered by the licensing framework.

At the same time, the expanded remdesivir licensing arrangements provide a potential mechanism for future access if the WHO-sponsored PARTNERS trial supports its use against Ebola BVD and regulatory requirements are met.

The donations of more than 38,000 remdesivir vials to the DRC, Uganda, and Kenya further demonstrate Gilead’s participation in the current outbreak response through investigational and compassionate-use activities.

Together, these initiatives reflect the company’s efforts to connect scientific development with practical access planning.

Preparing for Potential Future Access While Clinical Research Continues

The agreements with Dr. Reddy’s Laboratories, Eva Pharma, and Ferozsons Laboratories represent an important step in Gilead’s efforts to prepare for potential future access to obeldesivir for Ebola BVD post-exposure prophylaxis.

While the EBO-PEP Phase 3 trial continues to evaluate the investigational antiviral, technology transfer discussions and manufacturing preparations are already underway. Additional licensing agreements are also under discussion, potentially broadening the network of manufacturers capable of supplying the medicine if clinical evidence and regulatory approvals support its use.

The company’s parallel efforts involving remdesivir, including expanded licensing arrangements and donations to countries affected by the outbreak, further demonstrate its commitment to supporting Ebola-related research and response activities.

Ultimately, the potential impact of these initiatives will depend on the outcomes of ongoing clinical studies, regulatory decisions, and the ability of manufacturing and distribution partners to deliver medicines where they are needed.

By advancing clinical research and access planning simultaneously, Gilead aims to help ensure that potential antiviral options are better positioned to reach vulnerable populations if they are shown to be safe and effective and receive the necessary approvals.

About Obeldesivir

Obeldesivir is an investigational antiviral that has been evaluated in clinical trials for COVID-19 and respiratory syncytial virus (RSV) and has demonstrated preclinical activity across multiple filoviruses. It is currently being evaluated in the Ebola Post-Exposure Prophylaxis (EBO-PEP) trial, a partner-led Phase 3 randomized, placebo-controlled field trial evaluating the efficacy of obeldesivir as post-exposure prophylaxis (PEP) for individuals at high risk of developing Ebola Bundibugyo virus disease (BVD). Obeldesivir is not approved for the PEP of filovirus disease or for any indication in any country.

About Remdesivir

Remdesivir is a nucleotide analog prodrug invented and developed by Gilead, building on more than a decade of the company’s antiviral research. Remdesivir has broad-spectrum antiviral activity both in vitro and in animal models against multiple viral pathogens, including Marburg, Ebola, SARS, MERS and SARS-CoV-2, the virus that causes COVID-19.

Remdesivir has been approved as a COVID-19 treatment in approximately 50 countries worldwide. To date, remdesivir has been made available to more than 14.5 million patients around the world, including more than 8.1 million people in middle- and low-income countries through Gilead’s voluntary licensing program.

The clinical efficacy of remdesivir for the treatment of Ebola BVD has not been established. Remdesivir is currently not approved in any country for the treatment or prevention of Ebola BVD.

For more information about Gilead’s commitment to global health, visit Gilead.com.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation.

In 2025, Gilead announced a $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter